title: Effect of subpressor dose of angiotensin II on pain-related behavior in relation with neuronal injury and activation of satellite glial cells in the rat dorsal root ganglia.
abstract: To clarify the role of angiotensin II (Ang II) in the regulation of sensory signaling, we studied the effect of subpressor dose (150 ng/kg/min) of Ang II on pain-related behavior in relation with neuronal injury and activation of satellite glial cells (SGCs) in the dorsal root ganglia (DRGs) after chronic constriction injury (CCI). Systemic continuous delivery of Ang II induced the tactile, heat and cold hyperlagesia, when measured at 7 days ofpost-injury. Blockade of the AT1 receptor with losartan (2.5 mg/kg/day) prevented tactile hyperalgesia and attenuated cold hyperalgesia, but did not affect the response to noxious heat stimulus. A marked increase of large-sized injured primary afferent neurons, detected by ATF3 immunolabeling, was seen in lower lumbar DRGs on ipsilateral side after Ang II treatment. Subpressor dose of Ang II induced an increase of activated SGCs (detected by GFAP immunolabeling) enveloping large-diameter neurons. Our results suggested that Ang II through the AT1 receptor activation is an important regulatory factor in neuropathic pain perception and plays an important role in the injury of large-sized primary afferent neurons and activation of SGCs elicited by the CCI.
authors.affiliation: Institute of Neurobiology, Slovak Academy of Sciences, Kosice, Slovak Republic. pavel@saske.sk
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Pavel
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Oroszova
authors.forename: Ludmila
authors.initials: L
authors.lastname: Hricova
authors.forename: Nadezda
authors.initials: N
authors.lastname: Lukacova
mesh_terms: D051700:Activating Transcription Factor 3 / Q000378:metabolism; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole / Q000187:drug effects; D005455:Fluorescent Antibody Technique; D005727:Ganglia, Spinal / Q000187:drug effects / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D008297:Male; D009437:Neuralgia / Q000473:pathology* / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D017288:Pain Threshold / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects; D027161:Satellite Cells, Perineuronal / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D013599:Systole / Q000187:drug effects; D013696:Temperature
chemical_list: D051700:Activating Transcription Factor 3; C497108:Atf3 protein, rat; D005904:Glial Fibrillary Acidic Protein; D000804:Angiotensin II
references.citation: Pharmacol Rev. 2001 Dec;53(4):597-652
references.pmid: 11734620
references.citation: Orthop Clin North Am. 1991 Apr;22(2):195-211
references.pmid: 2014118
references.citation: Neuron Glia Biol. 2010 Feb;6(1):3-10
references.pmid: 20604977
references.citation: Am J Physiol. 1998 May;274(5):E867-76
references.pmid: 9612245
references.citation: Brain Res. 2012 Jan 3;1427:65-77
references.pmid: 22050959
references.citation: Brain Res Brain Res Rev. 2005 Jun;48(3):457-76
references.pmid: 15914252
references.citation: Pain. 2003 Jan;101(1-2):65-77
references.pmid: 12507701
references.citation: Neuroscience. 2005;132(2):453-63
references.pmid: 15802196
references.citation: Nat Neurosci. 2007 Nov;10(11):1361-8
references.pmid: 17965656
references.citation: Pharmacol Rev. 2000 Sep;52(3):415-72
references.pmid: 10977869
references.citation: Brain Res Bull. 2002 Jun;58(2):161-71
references.pmid: 12127013
references.citation: Pain. 1988 Apr;33(1):87-107
references.pmid: 2837713
references.citation: J Pain Res. 2012;5:31-8
references.pmid: 22375099
references.citation: Pain. 2009 May;143(1-2):114-22
references.pmid: 19307059
references.citation: Brain Res. 2011 Jun 17;1396:1-10
references.pmid: 21561603
references.citation: Br J Pharmacol. 2003 May;139(1):49-58
references.pmid: 12746222
references.citation: Neuroscience. 2009 Feb 18;158(4):1301-10
references.pmid: 19116162
references.citation: Neurosci Biobehav Rev. 2009 Jun;33(6):784-92
references.pmid: 19167424
references.citation: Brain Res. 2008 Dec 30;1246:111-22
references.pmid: 18976642
references.citation: Brain. 1997 Mar;120 ( Pt 3):445-9
references.pmid: 9126056
references.citation: Eur J Pharmacol. 2007 Jun 14;564(1-3):80-7
references.pmid: 17397823
references.citation: Neurol Res. 2008 Sep;30(7):751-60
references.pmid: 18498681
references.citation: Neuroscientist. 2009 Oct;15(5):450-63
references.pmid: 19826169
references.citation: Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H1890-9
references.pmid: 12907423
references.citation: Clin Sci (Lond). 2012 Nov;123(10):567-90
references.pmid: 22827472
references.citation: Life Sci. 2000 Oct 13;67(21):2577-85
references.pmid: 11104359